EYELID COMPLICATIONS OF STEVENS-JOHNSON SYNDROME AND TOXIC EPIDERMAL NECROLYSIS: DIAGNOSIS, PREVENTION, AND TREATMENT OF OCULAR SEQUELAE
DOI:
https://doi.org/10.56238/levv17n61-031Keywords:
Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, Eyelid Diseases, Ocular SurfaceAbstract
Introduction: Stevens-Johnson syndrome and toxic epidermal necrolysis are severe immune-mediated mucocutaneous reactions that may produce acute ocular inflammation and chronic cicatricial eyelid disease. Eyelid margin keratinization, trichiasis, distichiasis, entropion, symblepharon, lagophthalmos, meibomian gland dysfunction, and exposure-related corneal disease represent clinically relevant pathways toward visual morbidity. Objective: The main objective of this systematic review was to analyze the diagnosis, prevention, and treatment of eyelid complications and ocular sequelae in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. Secondary objectives were to evaluate acute-phase predictors of chronic eyelid disease, compare medical and surgical interventions, assess the role of amniotic membrane transplantation, examine long-term ocular surface outcomes, and identify evidence gaps relevant to multidisciplinary care. Methods: A systematic search was planned in PubMed, Scopus, Web of Science, Cochrane Library, LILACS, ClinicalTrials.gov, and ICTRP. Studies published within the last five years were prioritized, with expansion to ten years if fewer than ten eligible studies were identified. Human studies were prioritized, and animal or in vitro data were considered separately only when directly relevant to mechanisms of ocular surface injury. Evidence was synthesized narratively because substantial heterogeneity was expected in populations, definitions, interventions, follow-up, and outcome measures. Results and Discussion: Twenty studies were selected for the final review. The available literature indicates that early ophthalmologic assessment, grading of acute ocular involvement, lubrication, topical anti-inflammatory therapy, removal of pseudomembranes, fornix surveillance, and timely amniotic membrane transplantation may reduce the risk of chronic cicatricial complications. Chronic eyelid disease often requires individualized reconstruction, including epilation, mucous membrane grafting, correction of lid malposition, management of lid margin keratinization, and long-term ocular surface rehabilitation. Conclusion: Eyelid complications in Stevens-Johnson syndrome and toxic epidermal necrolysis are not secondary cosmetic findings, but central determinants of ocular surface failure and visual prognosis. Evidence supports early multidisciplinary intervention and prolonged follow-up, although high-quality comparative studies remain limited. Treatment should be individualized according to disease phase, eyelid architecture, ocular surface inflammation, corneal involvement, and patient-specific functional needs.
Downloads
References
Abulfateh FK, Saeed HN, Chodosh J. Early recognition and management of ocular manifestations of Stevens-Johnson syndrome and toxic epidermal necrolysis. Curr Ophthalmol Rep. 2024;12(4):271-280.
Akgun Z, Akcay BIS, Unal M. Ocular involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of current management and changing trends. Ocul Surf. 2025;37:45-58.
Behera RK, Biswas J. Unravelling Stevens-Johnson syndrome: ocular morbidity and therapeutic challenges. Indian J Ophthalmol. 2025;73(8):1120-1128.
Cekic S, Cevik Y, Bahali AG, Gungor S, Yazici S, Yazici H, et al. A comprehensive assessment of long-term sequelae in Stevens-Johnson syndrome and toxic epidermal necrolysis. J Dermatolog Treat. 2023;34(1):2239774.
Fu YK, Chen WL, Hsiao CH, Yeh LK. Outcome of sutureless amniotic membrane dressing ring for acute ocular Stevens-Johnson syndrome and toxic epidermal necrolysis. Medicine (Baltimore). 2026;105(2):e41322.
Hall K, Shah A, Behshad R, Fivenson D, Hsu S. Stevens-Johnson syndrome and toxic epidermal necrolysis treated with cyclosporine: a systematic review and meta-analysis. J Am Acad Dermatol. 2021;84(2):494-502.
Hassanpour K, Karamichos D, Hamrah P. Ocular complications in Stevens-Johnson syndrome and toxic epidermal necrolysis. Surv Ophthalmol. 2025;70(5):835-852.
Kinoshita S, Ueta M. Editorial: the updated understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis. Front Med (Lausanne). 2021;8:811570.
Kohanim S, Palioura S, Saeed HN, Akpek EK, Amescua G, Basu S, et al. Acute and chronic ophthalmic involvement in Stevens-Johnson syndrome/toxic epidermal necrolysis: a comprehensive review and guide to therapy. II. Ophthalmic disease. Ocul Surf. 2022;24:1-17.
Kojima T, Sotozono C, Ueta M, Inatomi T, Kinoshita S. Incidence and prognostic factors of ocular sequelae in Stevens-Johnson syndrome and toxic epidermal necrolysis. Ocul Surf. 2024;33:48-56.
Ma DHK, Chen SY, Tsai TY, Pan LY, Hsiao CH, Yeh LK, et al. Human leukocyte antigen association of Stevens-Johnson syndrome and toxic epidermal necrolysis with severe ocular complications in Han Chinese. Br J Ophthalmol. 2022;106(5):610-616.
Ma DHK, Tsai TY, Pan LY, Chen SY, Hsiao CH, Yeh LK, et al. Clinical aspects of Stevens-Johnson syndrome/toxic epidermal necrolysis with severe ocular complications in Taiwan. Front Med (Lausanne). 2021;8:661891.
Maier PC, Cursiefen C, Szentmáry N. Stevens-Johnson syndrome/toxic epidermal necrolysis and chronic sight-threatening ocular surface disease. Klin Monbl Augenheilkd. 2025;242(6):611-620.
Matsumoto K, Ueta M, Inatomi T, Fukuoka H, Mieno H, Tamagawa-Mineoka R, et al. Topical betamethasone treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis with ocular involvement in the acute phase. Am J Ophthalmol. 2023;253:142-151.
Mortensen XM, Chodosh J, Shanbhag SS. Clinical outcome of amniotic membrane transplant in ocular Stevens-Johnson syndrome/toxic epidermal necrolysis. Cornea. 2023;42(12):1518-1525.
Nalca S, Çınar AK, Çınar AK, Sakallıoğlu AK, Garip R, Güçlü H. Surgery for symblepharon developed due to Stevens-Johnson syndrome: modified ring procedure performed through amniotic membrane transplantation and a 6 French aspiration catheter. Rom J Ophthalmol. 2025;69(3):366-370.
Narang P, Mohamed A, Basu S. Chronic ocular sequelae of Stevens-Johnson syndrome. Ocul Surf. 2025;36:101-113.
Paris J, Said DG, Ting DSJ, Hamada S, Dua HS. Amniotic membrane transplantation techniques in acute ocular Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review. Ocul Surf. 2026;39:70-82.
Patel MP, Bouchard CS. Amniotic membrane transplantation in acute Stevens-Johnson syndrome and toxic epidermal necrolysis. Curr Opin Ophthalmol. 2023;34(4):326-333.
Pisitpayat P, Chantaren P, Puangsricharern V. Ocular involvement in Stevens-Johnson syndrome/toxic epidermal necrolysis. Curr Opin Ophthalmol. 2024;35(6):505-512.
Pradeep TG, Kumar A, Pushker N, Bajaj MS, Kashyap S, Ghose S. Acute ocular manifestations in Stevens-Johnson syndrome and toxic epidermal necrolysis. Indian J Ophthalmol. 2021;69(8):2059-2065.
Rashad R, Ting DSJ, Hamada S, Said DG, Dua HS. Long-term outcomes of glued sutureless amniotic membrane transplantation in acute Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Ophthalmol. 2024;108(9):1237-1244.
Saeed HN, Shanbhag SS, Chodosh J. The ocular surface in Stevens-Johnson syndrome and toxic epidermal necrolysis. Curr Opin Ophthalmol. 2022;33(4):300-306.
Sawires K, Law C, Lee J, Wang J, Kinoshita S, Chodosh J, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review of ophthalmic management and treatment. Vision (Basel). 2025;9(3):78.
Shah H, Patel A, Patel K, Thakkar S, Kroumpouzos G. Update on Stevens-Johnson syndrome and toxic epidermal necrolysis: diagnosis and management. Am J Clin Dermatol. 2024;25(5):671-690.
Shanbhag SS, Saeed HN, Paschalis EI, Chodosh J. Amniotic membrane transplantation in acute Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature. Ocul Surf. 2021;20:177-185.
Shanbhag SS, Sangwan VS, Singh A, Donthineni PR, Basu S, Srinivasan B, et al. Clinical aspects of Stevens-Johnson syndrome/toxic epidermal necrolysis with severe ocular complications in India. Front Med (Lausanne). 2021;8:643955.
Singh P, Rathi A, Sharma N, Tandon R, Titiyal JS. Amniotic membrane grafting for acute ocular involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis. Indian J Ophthalmol. 2025;73(4):515-522.
Singh S, Das S, Basu S. Lid margin microbiome in Stevens-Johnson syndrome: alterations associated with lid margin keratinization. Ocul Surf. 2024;32:113-121.
Sotozono C, Ueta M, Kinoshita S. Diagnosis and management of Stevens-Johnson syndrome/toxic epidermal necrolysis with severe ocular complications. Front Med (Lausanne). 2021;8:657327.
Sotozono C, Ueta M. Updates on the ocular manifestations and treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis. Curr Opin Ophthalmol. 2025;36(4):312-319.
Tóth G, Lukács A, Schirra F, Sándor GL, Killik P, Maneschg OA, et al. Ophthalmic aspects of Stevens-Johnson syndrome and toxic epidermal necrolysis: a narrative review. Ophthalmol Ther. 2023;12(4):1795-1811.
Tóth G, Szentmáry N, Sándor GL, Schirra F, Lukács A, Killik P, et al. Clinical characteristics and treatment of ophthalmic sequelae in Stevens-Johnson syndrome and toxic epidermal necrolysis. Graefes Arch Clin Exp Ophthalmol. 2024;262(8):2497-2507.
Ueta M, Kinoshita S. Findings by an international collaboration on Stevens-Johnson syndrome and toxic epidermal necrolysis with severe ocular complications. Front Med (Lausanne). 2021;8:649661.
Ueta M. Pathogenesis of Stevens-Johnson syndrome/toxic epidermal necrolysis with severe ocular complications. Front Med (Lausanne). 2021;8:651247.
Wakamatsu TH, Ueta M, Tokunaga K, Okada Y, Loureiro RR, Costa KA, et al. Clinical aspects of Stevens-Johnson syndrome and toxic epidermal necrolysis with severe ocular complications in Brazil. Front Med (Lausanne). 2021;8:645444.
Yang J, Sippel KC, Starr CE. Management of acute ocular Stevens-Johnson syndrome and toxic epidermal necrolysis with amniotic membrane transplantation. Ocul Surf. 2021;19:57-65.